The Green Scoop That Built a $600 Million Habit

The object is almost comically modest: a scoop, a glass, eight to twelve ounces of cold water. Stir or shake. Drink. In the crowded theater of modern wellness, where the cast includes gummy bears, cold plunges, glucose monitors and cabinets that rattle with capsules, AG1 made its fortune by shrinking the performance. It turned the anxious question "Am I getting enough?" into one green answer before breakfast.

That answer is a powdered dietary supplement combining a multivitamin, minerals, prebiotics, probiotics, superfoods and antioxidants. The company calls it a Daily Health Drink and "foundational nutrition," a phrase chosen to sit beneath the rest of life rather than replace it. The practical appeal is plainer: fewer bottles, fewer decisions and a recurring delivery before the pouch runs dry.

The business behind the glass is less modest. Forbes reported that AG1 expected about $600 million in annual revenue in 2024, up from $160 million in 2021, while operating profitably. The company says millions of customers have used the product. A 2022 financing put its pre-money valuation at $1.2 billion. For most of that climb, AG1 resisted the usual consumer-brand reflex to fill every shelf. One formula, mainly sold direct, was the point.

A supplement cabinet in compression

Founder Chris Ashenden arrived at the idea through frustration. After extensive testing for his own recurring health problems, he was given a regimen of roughly 50 pills. He began developing a more convenient alternative, launched in 2010 as Ultimate Greens Daily. The name became Athletic Greens and, in 2021, AG1. The formula changed more often than the branding: the company says it has made more than 50 iterations, moving to selected methylated nutrients in 2012, adding the adaptogen rhodiola in 2016 and removing ingredients when new evidence or formulation work demanded it.

The customer is not necessarily an elite athlete. It is an adult with enough health intent to buy supplements and enough friction in the morning to value consolidation: a frequent traveler, a busy parent, a professional eating lunch between calls, a runner who wants a product screened for banned substances. AG1 is vegan, gluten-free and NSF Certified for Sport. That certification means independent review, facility audits and testing associated with label accuracy and prohibited substances. It matters to athletes, but it also operates as a trust mark for people whose only competition that day is a calendar.

AG1's most defensible ingredient may be the decision it removes.

This is where the company differs from a basic greens powder. It does not primarily sell vegetables in powdered form, and it should not be mistaken for a salad. It sells a broad supplement bundle with a ritual attached. The original flavor - lightly pineapple and vanilla - is engineered to be agreeable enough for repetition. The branded shaker, scoop, travel packs and 30-day subscription cadence make the behavior visible and portable. The product is the powder; the system is remembering to use it.

The podcast-to-pouch machine

AG1's route to market was native to the internet. Long before greens crowded supermarket aisles, host-read podcast advertisements and creator partnerships placed the pouch inside trusted conversations about productivity, performance and health. A creator could describe a personal morning, supply a promo code and offer free travel packs. The sale landed on AG1's own website, where the company controlled the education, checkout and renewal.

The economics are straightforward. In the United States, AG1 Next Gen is advertised at $99 for a one-time 30-serving pouch or $79 with a monthly subscription, typically bundled with shipping, a welcome kit, travel packs and vitamin D3+K2 drops. That is a premium price in a field where Huel Daily Greens, Bloom, Live it Up, Amazing Grass, Organifi and Jocko Greens compete with cheaper servings, different flavors or claims of more transparent dosing. Ordinary multivitamins and a varied diet remain the less theatrical alternatives.

The debate begins where the neat bundle meets nutritional specificity. AG1 lists every ingredient, but some sit inside proprietary blends without an individual amount. Dietitians have noted that this makes it difficult to judge whether each botanical appears at a dose used in research. The drink also does not provide the fiber of whole fruits and vegetables, and vitamin D is handled through separate drops. A long label can signal breadth; it does not automatically prove that every item is doing meaningful work.

AG1's response has been to study the finished formula, not merely cite research on its components. The company says AG1 Next Gen was evaluated across four randomized, placebo-controlled trials concerning nutrient gaps, bioavailability and aspects of gut health. It also announced a $20 million, three-year research commitment and a partnership with UC Davis's Innovation Institute for Food and Health. In 2026 it added independent science and innovation advisers and opened a program for healthcare practitioners. The strategic direction is clear: an influencer-built brand wants clinical credibility sturdy enough for a clinic.

What happens after one?

For years, AG1's discipline was easy to narrate. CEO Kat Cole described the company in 2024 as having a singular focus on one product sold primarily through direct-to-consumer channels. Cole had joined as president and chief operating officer in 2021, after leading large restaurant brands, and became chief executive in July 2024. She inherited a valuable constraint: customers understood exactly what AG1 meant.

The operating model was unusual too. AG1 has described itself as remote from its early years, with team members spread across more than 16 countries by 2025. That arrangement suited a company whose storefront, customer service and marketing were already digital, but global distribution made the physical work harder: botanical ingredients vary by harvest and origin, while flavor and texture must arrive predictably in every pouch. AG1's 2025 impact report said 90 percent of its ingredient purchases were traceable to origin. The statistic is less glamorous than a new flavor, and more revealing. Scaling a daily ritual requires making agricultural variability invisible to the person holding the scoop.

Then, in 2025, nearly every word in the old formula changed. AG1 Next Gen increased a serving from 12 to 13 grams, added five probiotic strains and more nutrients, and arrived after several whole-formula studies. Citrus, Berry and Tropical joined Original after about 300 prototypes. The classic formula entered all US Costco stores. In September, the company announced AGZ, a melatonin-free nighttime drink containing magnesium L-threonate, saffron and L-theanine among its highlighted ingredients.

That expansion is logical and risky in equal measure. More flavors reduce taste objections. Costco reaches people who never hear the right podcast. AGZ doubles the addressable day by moving from morning to bedtime. A practitioner program adds affiliate and wholesale paths for clinicians. But every addition complicates the original argument that one product was enough. If the foundation now needs a nighttime annex, a customer might reasonably ask where the building ends.

The wider market is pushing in the same direction. Greens powders have become a recognizable category, with value brands below AG1 and adjacent formats such as gummies attacking the inconvenience of mixing. AG1 occupies the premium, brand-led corner: more polished than a commodity tub, broader than a conventional vitamin, less nutritionally complete than a meal replacement. Its advantages are awareness, recurring behavior, certification, testing and years of formulation experience. Its vulnerability is that convenience can be copied while trust has to be renewed.

The ritual is the moat

The useful lesson in AG1 is not that every consumer company should stuff 75-plus ingredients into a pouch. It is that complexity can be moved off the customer's side of the counter. AG1 absorbs sourcing, formulation, flavoring, bundling and replenishment, then leaves the customer with one visible motion. That clarity supported bootstrapping for roughly 11 years before the company accepted outside investment. In January 2022, it raised $115 million from Alpha Wave Global and a collection of returning and strategic investors.

The next test is whether AG1 can preserve that clarity while becoming a multi-product, multi-channel nutrition company. The early evidence is a carefully sequenced expansion: upgrade the formula, add flavor, add retail, add a second time of day, then invite practitioners and research institutions closer. Irish Rugby joined as a multi-year partner in 2026, extending the brand's performance credentials from podcast conversation to the pitch.

None of this makes the green drink essential, universal or a replacement for food. It makes AG1 a revealing consumer business. The company noticed that people do not only struggle to know what is healthy; they struggle to repeat healthy intentions when mornings become untidy. A scoop is a small piece of industrial design for that problem. Whether the next phase becomes a durable platform or a crowded cupboard will depend on AG1 remembering the constraint that made it famous: the customer came for less to think about.